Mutant LRRK2 causes a delay in early-to-late and late endosomal trafficking, and fibroblasts from PD patients with pathogenic LRRK2 mutations show decreased Rab7 activity compared to healthy controls (Gomez-Suaga et al., 2014). This evidence concerns the gene LRRK2 and Parkinson disease.